Tirzepatide beats older GLP-1 drugs for weight loss, at a gut-side-effect cost

Obesity remains one of the hardest conditions to treat with lifestyle change alone, and the arrival of hormone-based drugs has reset expectations for what medication can achieve. Tirzepatide is a newer entrant, originally developed as a glucose-lowering drug, and the pressing question is how it stacks up against the established options: GLP-1 receptor agonists, insulin and placebo. Efficacy is only half of that question, because a weight loss drug also has to be tolerable and safe enough to take for the long haul. This review pooled the randomised trial evidence to weigh both sides of the ledger.

The authors searched PubMed, the Cochrane Library, Embase and Web of Science from each database's start to May 2023 for randomised controlled trials of tirzepatide in overweight and obesity. Twelve trials qualified, together enrolling 11,758 patients. The team extracted data on body mass index, waist circumference and body weight, compared tirzepatide against GLP-1 receptor agonists, placebo and insulin, and assessed risk of bias across the included studies. Safety outcomes covered gastrointestinal reactions, low blood sugar and a range of rarer adverse events including pancreatitis, gallbladder inflammation, cardiovascular events and tumours.

Tirzepatide beat all three comparators on every weight measure. It reduced BMI by 1.71 units more than GLP-1 receptor agonists, 3.99 more than placebo and 4.02 more than insulin, with similar advantages in waist circumference and body weight, and the effect grew with dose. People on tirzepatide were also dramatically more likely than those on placebo to lose a fifth, or even a quarter, of their body weight. Gastrointestinal side effects were markedly more common than with placebo or insulin and slightly more common than with GLP-1 receptor agonists, while the risk of low blood sugar was significantly lower than with insulin. Rates of pancreatitis, cholecystitis, major cardiovascular events, hypersensitivity reactions and neoplasms did not differ significantly.

These results place tirzepatide ahead of the GLP-1 receptor agonist class it is often grouped with, at least on the weight outcomes pooled here. That matters because GLP-1 drugs had already transformed pharmacological weight loss, and this analysis suggests the bar has moved again. The pooled safety picture is broadly reassuring on rare harms, though gut tolerability is a recurring theme for this whole class of medicines. Longer-term questions, including how durable the weight loss is and what happens after stopping, sit outside what these trials can answer.

For readers following the rise of weight loss medication, this is the clearest pooled comparison yet suggesting tirzepatide outperforms the established GLP-1 receptor agonists as well as placebo and insulin on weight, BMI and waist size. It also confirms the cost of entry: nausea and other gastrointestinal complaints are common enough to need vigilance. This is prescription medicine territory, decided between a patient and a clinician, and nothing here speaks to how the drug compares with, or combines with, diet and training approaches.